Sun Pharmaceuticals rating – Buy: One-offs impacted the bottomline in Q4
Monday, May 31, 2021, 20:45
Steady progress in sales of specialty products; the momentum is likely to be sustained; ‘Buy’ retained with TP raised to Rs 815
You can follow any responses to this entry through the
RSS 2.0 feed.